Lineage Cell Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders' Equity
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Other · Total | ||||||
| Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2023 | 174,987 | $451,343 | $(384,856) | $(1,396) | $(3,068) | $62,023 |
| Shares issued through registered direct financing | 13,462 | 14,000 | — | — | — | 14,000 |
| Shares issued through ATM | 30 | 37 | — | — | — | 37 |
| Financing related fees | — | (112) | — | — | — | (112) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 45 | (23) | — | — | — | (23) |
| Shares issued upon exercise of stock options | 230 | 163 | — | — | — | 163 |
| Stock-based compensation | — | 1,163 | — | — | — | 1,163 |
| Unrealized loss on marketable debt securities | — | — | — | — | (1) | (1) |
| Foreign currency translation adjustment | — | — | — | — | 298 | 298 |
| Net loss | — | — | (6,542) | (16) | — | (6,558) |
| BALANCE - March 31, 2024 | 188,754 | $466,571 | $(391,398) | $(1,412) | $(2,771) | $70,990 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Other · Total | ||||||
| Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2022 | 170,093 | $440,280 | $(363,370) | $(1,403) | $(3,571) | $71,936 |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 53 | (37) | — | — | — | (37) |
| Shares issued upon exercise of stock options | 28 | 25 | — | — | — | 25 |
| Stock-based compensation | — | 1,031 | — | — | — | 1,031 |
| Unrealized gain on marketable debt securities | — | — | — | — | 91 | 91 |
| Foreign currency translation adjustment | — | — | — | — | 373 | 373 |
| Net loss | — | — | (4,372) | (32) | — | (4,404) |
| BALANCE - March 31, 2023 | 170,174 | $441,299 | $(367,742) | $(1,435) | $(3,107) | $69,015 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.